Celgene-backed GlobeImmune's flotation is still pending, as of this article, having been reportedly delayed last week.
Biopharmaceutical company GlobeImmune delayed its planned initial public offering without explanation last week, according to news provider MarketWatch.
The Louisville-based firm was looking to raise $60m to $74m in its IPO, which it filed with the SEC in July. The company said earlier this month that it planned to offer 5 million shares between $11 and $13. Wells Fargo and Jefferies were serving as co-lead underwriters.
The firm has raised $115.1m in venture funding.
In January 2010, investment manager Generali…
